GILD Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NASDAQ. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 6 comparable calls have settled; 33.3% reached the published sell target. Information only, not financial advice.
In the sell zone
Price has run up to the upper trend line — the level it has repeatedly stalled at.
Read from the last 7 months of history we hold: falling, drifting −10% a year. Price is above both fitted ceilings, so there is no line overhead to break — and no fitted resistance to price the target against either. What would overturn this: a close below US$137.39 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 7 months read from
- US$137.39 – US$144.41 Falling channel, −10% a year
- Position in that channel
- 147% above the ceiling of it — 0% is the floor, 100% the ceiling
What broke this trend
- The fall
- -22% from US$153.8411 Feb 2026 → 10 June 2026
- Whose problem it was
- This company0 of 7 Drug Manufacturers - General peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 82%of what it lost
- What the record says
- 86% of 12 comparable falls came back, typically in 128 days measured on its own peer group
The trend broke in February 2026: price fell 22% from 153.84 to 120.67 by June 2026, and has regained 82% of that fall since. Its peers did not fall with it, so this was about the company rather than its sector. The wire that week: “FDA Approves Label Update For Gilead's Kite's Yescarta”. Falls like it have resolved: falls of about 22% here have come back to the old high 86% of the time (12 comparable falls), typically in 128 days. On that record the fall is treated as temporary, and the trend lines are fitted to the regime it created rather than through it.
Reported at the time: FDA Approves Label Update For Gilead's Kite's Yescarta — 6 Feb 2026
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (7 months)
- Lower trend line (7 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
We replayed these rules over this stock's own history and the target was reached on only 2 of 6 calls. Its swings do not respect the channel reliably enough for a published call, and no alerts are sent. The numbers below are still this site's read of the fitted channel.
Buy at or below
US$137.40
level as at 17 Sept 2026
Our target
US$150.19
by 16 Dec 2026
Projected move
9.3%
gross, before costs
Price sits between our buy level and our target.
On this stock's own history these rules produced 6 settled calls, of which 2 reached target (33.3%), with an average best move of 5.4%. See the full record.
- Upper line touches
- 3
- Lower line touches
- 2
- Fit confidence
- 74%
- Fitted
- 17 Sept 2026
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day
- Employees
- 17,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$187.47B
- Enterprise value
- —
- Beta
- 0.35
- Avg volume
- 7.13M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 108.46-157.29
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.